Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NUCLEUS - FORENINGEN AF DANSKE BIOLOGERS FORLAG ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%   Bankruptcy risk   1.6% 3.8% 1.5% 3.3% 1.1% 1.6% 6.6% 6.5%   Credit score (0-100)   76 51 76 55 82 75 36 37   Credit rating   A BBB A BBB A A BBB BBB   Credit limit (kDKK)   22.5 0.0 65.2 0.0 368.0 32.1 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   2,661 2,465 3,341 2,560 3,334 3,165 0.0 0.0   EBITDA   -167 -1,380 542 -320 362 -27.3 0.0 0.0   EBIT   -167 -1,380 542 -338 276 -239 0.0 0.0   Pre-tax profit (PTP)   644.7 -1,017.0 993.7 -1,456.4 897.9 411.4 0.0 0.0   Net earnings   502.9 -793.4 775.1 -1,136.0 700.3 310.9 0.0 0.0   Pre-tax profit without non-rec. items   645 -1,017 994 -1,456 898 411 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 36.7 33.4 841 0.0 0.0   Shareholders equity total   11,374 10,580 11,355 10,223 10,923 11,234 10,922 10,922   Interest-bearing liabilities   0.0 8.3 0.0 43.4 37.3 5.4 0.0 0.0   Balance sheet total (assets)   12,991 13,906 13,984 11,261 12,351 12,818 10,922 10,922   Net Debt   -10,984 -10,857 -10,195 -7,135 -7,616 -7,339 -10,922 -10,922     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   2,661 2,465 3,341 2,560 3,334 3,165 0.0 0.0   Gross profit growth   22.4% -7.4% 35.5% -23.4% 30.2% -5.1% -100.0% 0.0%   Employees   4 4 4 5 4 5 0 0   Employee growth %   0.0% 0.0% 0.0% 25.0% -20.0% 25.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   12,991 13,906 13,984 11,261 12,351 12,818 10,922 10,922   Balance sheet change%   5.2% 7.0% 0.6% -19.5% 9.7% 3.8% -14.8% 0.0%   Added value   -167.5 -1,380.1 541.6 -319.7 294.7 -27.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 107 23 507 -952 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 1.0 -1.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -6.3% -56.0% 16.2% -13.2% 8.3% -7.5% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   5.1% -7.5% 7.2% -2.7% 7.8% 4.7% 0.0% 0.0%   ROI %   5.8% -9.1% 9.0% -3.1% 8.6% 4.1% 0.0% 0.0%   ROE %   4.5% -7.2% 7.1% -10.5% 6.6% 2.8% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   87.6% 76.1% 81.2% 90.8% 88.4% 87.6% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   6,558.2% 786.7% -1,882.2% 2,232.1% -2,105.0% 26,905.4% 0.0% 0.0%   Gearing %   0.0% 0.1% 0.0% 0.4% 0.3% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 46.8% 189.1% 5,151.3% 42.7% 211.6% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   7.8 4.0 4.7 8.4 6.8 5.5 0.0 0.0   Current Ratio   8.4 4.5 5.3 10.6 8.4 7.4 0.0 0.0   Cash and cash equivalent   10,983.5 10,865.7 10,194.6 7,178.2 7,653.2 7,344.4 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,886.9 874.0 2,198.1 2,840.8 3,403.5 3,332.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -42 -345 135 -64 74 -5 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -42 -345 135 -64 90 -5 0 0   EBIT / employee   -42 -345 135 -68 69 -48 0 0   Net earnings / employee   126 -198 194 -227 175 62 0 0